Current Status of Immunotherapies for Treating Pancreatic Cancer
- 85 Downloads
Purpose of Review
Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed.
We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials.
As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.
KeywordsPancreatic adenocarcinoma Immunotherapy Cancer vaccines
Compliance with Ethical Standards
Conflict of Interest
Annie A. Wu declares that she has no conflict of interest.
Elizabeth Jaffee has received research funding from Adaptive Biotech, IM Core (Genentech), Lustgarten Foundation, Bristol-Myers Squibb, Breast Cancer Research Foundation, Amgen, and Aduro BioTech; has received travel reimbursement and an honorarium from Adaptive Biotech; has received travel reimbursement and honoraria for participating on scientific advisory boards from Dragonfly Therapeutics, CStone Pharmaceuticals, Genocea Biosciences, Parker Institute, and Lustgarten Foundation; and GVAX and Listeria monocytogenes—Mesothelin are both licensed to Aduro BioTech with the potential to receive royalties.
Valerie Lee declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Society, A.C., Cancer Facts & Figures 2019. Google Scholar
- 8.Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefPubMedGoogle Scholar
- 9.•• Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406 A randomized clinical trial of adjuvant therapy for patients with resected pancreas cancer. DFS at 3 years was 39.7% in FOLFIRINOX group versus 21.4% in gemcitabine group, and median OS was 54.4 months in FOLFIRINOX group versus 35.0 months in gemcitabine group. This shows significant improvement in survival for patients with pancreas cancer who were previously advised a median 28-month survival even with surgical intervention. CrossRefPubMedGoogle Scholar
- 12.Yuen A, Diaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl). 2014;2:91–106.Google Scholar
- 24.Andre T, Lonardi S, Wong KYM, Morse M, McDermott RS, Hill AG, et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. J Clin Oncol. 2017;35:3531.CrossRefGoogle Scholar
- 25.Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.• Cancer Genome Atlas Research Network. Electronic address: email@example.com; and N. Cancer Genome Atlas Research, Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2017. 32(2): p. 185–203 e13. The TCGA molecular characterizations of cancers have led to better understanding of the different classifications of tumors, and their heterogeneity. This allows for better targeted therapies for patients over time. Google Scholar
- 33.Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.•• Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13 In this landmark study, patients with refractory, metastatic cancers with mismatch repair deficiency were treated with PD-1 blockade with pembrolizumab. Fifty-three percent of patients had an objective response. This study led to the first FDA approval of tumor-agnostic therapy for pembrolizumab for these patients. CrossRefPubMedPubMedCentralGoogle Scholar
- 44.NCCN Guidelines for Patients: Pancreatic Cancer, Version 1. National Comprehensive Cancer Network, 2017.Google Scholar
- 55.Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology. 2014;146(7):1784–94 e6.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Corporation NG, NewLink genetics announces results from phase 3 IMPRESS trial of algenpantucel-L for patients with resected pancreatic cancer. Acquire Media, 2016.Google Scholar
- 66.Le DT, Ko AH, Wainberg ZA, Picozzi VJ, Kindler HL, Wang-Gillam A, et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). J Clin Oncol. 2017;35(4_suppl):345.CrossRefGoogle Scholar
- 67.Muscarella P, Wilfong LS, Ross SB, Richards DA, Raynov J, Fisher WE, et al. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup. J Clin Oncol. 2012;30:e14501.Google Scholar
- 76.• Ott PA, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21 A main barrier to development of personalized vaccines has been due to cost and timeliness of sequencing and development. This trial demonstrated the feasibility of developing an immunogenic vaccine in a reasonable time period to administer to high-risk melanoma patients in the adjuvant setting. CrossRefPubMedPubMedCentralGoogle Scholar
- 92.Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008;206(5):849–54 discussion 854-6.CrossRefPubMedGoogle Scholar